| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income (expenses), net | -123 | -93 | ||
| Loss before income taxes | -5,171 | -5,757 | ||
| Income tax provision | 10 | 4 | ||
| Net loss | -5,181 | -5,761 | ||
| Net loss attributable to noncontrolling interest | -32 | -46 | ||
| Net loss attributable to controlling interest | -5,149 | -5,715 | ||
| Deemed dividend on warrants | -5,673 | 0 | ||
| Net loss attributable to common stockholders | -10,822 | -5,715 | ||
| Net loss per share, basic | -2.21 | -1.99 | ||
| Net loss per share, diluted | -2.21 | -1.99 | ||
| Weighted average common shares outstanding, basic | 4,907 | 2,877 | ||
| Weighted average common shares outstanding, diluted | 4,907 | 2,877 | ||
Calidi Biotherapeutics, Inc. (CLDWW)
Calidi Biotherapeutics, Inc. (CLDWW)